valproic acid has been researched along with Basal Ganglia Diseases in 21 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 9.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "Aripiprazole is an atypical antipsychotic compound that is approved by the U." | 6.73 | Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. ( Blow, FC; Cassidy, KA; Coconcea, N; Hays, RW; Ignacio, RV; Meyer, WJ; Sajatovic, M, 2008) |
| "This 3-week randomized, double-blind, placebo-controlled study included 156 bipolar disorder patients with a current manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, risperidone, or haloperidol." | 5.10 | Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. ( Bowden, CL; Ghaemi, SN; Grossman, F; Okamoto, A; Sachs, GS, 2002) |
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 5.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "After a < or = 1-day screening period, 36 consecutive hospitalized patients with bipolar disorder, manic or mixed phase and with psychotic features, were randomly assigned to receive either divalproex 20 mg/kg/day or haloperidol 0." | 5.08 | A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. ( Bennett, JA; Keck, PE; McElroy, SL; Stanton, SP; Strakowski, SM; Tugrul, KC, 1996) |
| " For 80 patients treated with sodium valproate, the mean ± SD dosage was 1541." | 2.80 | Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. ( Asadollahi, S; Azadbakht, A; Hatamabadi, H; Heidari, K; Mirmohseni, L; Vafaee, R; Yunesian, S, 2015) |
| "Ziprasidone was well tolerated." | 2.77 | Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. ( Bachinsky, M; Cavus, I; Karayal, ON; Kolluri, S; Sachs, GS; Vanderburg, DG, 2012) |
| "Aripiprazole is an atypical antipsychotic compound that is approved by the U." | 2.73 | Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. ( Blow, FC; Cassidy, KA; Coconcea, N; Hays, RW; Ignacio, RV; Meyer, WJ; Sajatovic, M, 2008) |
| " The aim of this study was to compare the effectiveness and tolerability of topiramate and divalproex in combination with risperidone for treating acute mania patients in a naturalistic treatment setting." | 2.71 | Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. ( Bahk, WM; Choi, SK; Chung, SK; Jon, DI; Lee, JS; Pae, CU; Paik, IH; Shin, YC; Woo, JM; Yoon, BH, 2005) |
| "Pediatric migraine is a common, chronic, and disabling neurological disorder in children and adolescents." | 2.66 | Intravenous Migraine Treatment in Children and Adolescents. ( Hershey, AD; Kabbouche, M; Maconochie, I; Murphy, B; Qaiser, S; Werner, K, 2020) |
| "Weight gain was found to be lower in the elderly for antipsychotic drugs, in particular for olanzapine." | 1.39 | Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. ( Baumann, P; Greil, W; Grohmann, R; Häberle, A; Schuhmann, T, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Werner, K | 1 |
| Qaiser, S | 1 |
| Kabbouche, M | 1 |
| Murphy, B | 1 |
| Maconochie, I | 1 |
| Hershey, AD | 1 |
| Greil, W | 1 |
| Häberle, A | 1 |
| Schuhmann, T | 1 |
| Grohmann, R | 1 |
| Baumann, P | 1 |
| Asadollahi, S | 1 |
| Heidari, K | 1 |
| Hatamabadi, H | 1 |
| Vafaee, R | 1 |
| Yunesian, S | 1 |
| Azadbakht, A | 1 |
| Mirmohseni, L | 1 |
| Penot, JP | 1 |
| Pradeau, F | 1 |
| Sachs, GS | 3 |
| Vanderburg, DG | 1 |
| Karayal, ON | 1 |
| Kolluri, S | 1 |
| Bachinsky, M | 1 |
| Cavus, I | 1 |
| Murphy, JV | 1 |
| Yatham, LN | 1 |
| Grossman, F | 2 |
| Augustyns, I | 1 |
| Vieta, E | 1 |
| Ravindran, A | 1 |
| Bahk, WM | 1 |
| Shin, YC | 1 |
| Woo, JM | 1 |
| Yoon, BH | 1 |
| Lee, JS | 1 |
| Jon, DI | 1 |
| Chung, SK | 1 |
| Choi, SK | 1 |
| Paik, IH | 1 |
| Pae, CU | 1 |
| Nasrallah, HA | 1 |
| Brecher, M | 1 |
| Paulsson, B | 1 |
| Tahiroglu, AY | 1 |
| Avci, A | 1 |
| Sajatovic, M | 1 |
| Coconcea, N | 1 |
| Ignacio, RV | 1 |
| Blow, FC | 1 |
| Hays, RW | 1 |
| Cassidy, KA | 1 |
| Meyer, WJ | 1 |
| McElroy, SL | 1 |
| Keck, PE | 1 |
| Stanton, SP | 1 |
| Tugrul, KC | 1 |
| Bennett, JA | 1 |
| Strakowski, SM | 1 |
| Wils, V | 1 |
| Golüke-Willemse, G | 1 |
| Zarate, CA | 1 |
| Baldessarini, RJ | 1 |
| Siegel, AJ | 1 |
| Nakamura, A | 1 |
| McDonald, J | 1 |
| Muir-Hutchinson, LA | 1 |
| Cherkerzian, T | 1 |
| Tohen, M | 1 |
| Dose, M | 1 |
| Hellweg, R | 1 |
| Yassouridis, A | 1 |
| Theison, M | 1 |
| Emrich, HM | 1 |
| Conforti, D | 1 |
| Borgherini, G | 1 |
| Fiorellini Bernardis, LA | 1 |
| Magni, G | 1 |
| Guille, C | 1 |
| Ghaemi, SN | 2 |
| Okamoto, A | 1 |
| Bowden, CL | 1 |
| Lautin, A | 1 |
| Stanley, M | 1 |
| Angrist, B | 1 |
| Gershon, S | 1 |
| Snoek, JW | 1 |
| van Weerden, TW | 1 |
| Teelken, AW | 1 |
| van den Burg, W | 1 |
| Lakke, JP | 1 |
| Lang, AE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Three-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Add-On Oral Ziprasidone in Subjects With Acute Mania Treated With Lithium or Divalproex[NCT00312494] | Phase 3 | 680 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00250367] | Phase 3 | 151 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Aripiprazole in Late Life Bipolar Disorder[NCT00194038] | Phase 4 | 20 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00253149] | Phase 3 | 158 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
GAF measures the severity of illness-related impairment in psychological, social, and occupational functioning; rated on a 100-point scale (single score of 1 to 100) with 100 indicating superior functioning. Change calculated as mean of (value of GAF score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 3
| Intervention | scores on scale (Least Squares Mean) |
|---|---|
| Ziprasidone (Higher Dose) | 8.79 |
| Ziprasidone (Lower Dose) | 9.62 |
| Placebo | 7.79 |
LIFE-RIFT measures severity of illness-related impairment in 4 domains: work, interpersonal relations, recreation, and global satisfaction; has a total score and individual domain scores. Domain scores range from 1 to 5 (scores ≥ 2 reflect impaired functioning). Total score is sum of the 4 domains with range of 4 (very good) to 20 (very poor): higher scores indicate greater impairment. Change calculated as mean of (value of LIFE-RIFT score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 3
| Intervention | scores on scale (Least Squares Mean) |
|---|---|
| Ziprasidone (Higher Dose) | -1.68 |
| Ziprasidone (Lower Dose) | -1.58 |
| Placebo | -1.27 |
YMRS is an 11-item scale (elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, speech [rate and amount], language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight) used to assess the severity of manic symptoms and effect of treatment on mania severity. Seven items ranked on scale from 0 to 4; 4 items ranked 0 to 8. Total possible score 0 to 60: higher scores indicate greater severity. Change calculated as mean of (value of YMRS score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 3
| Intervention | scores on scale (Least Squares Mean) |
|---|---|
| Ziprasidone (Higher Dose) | -10.19 |
| Ziprasidone (Lower Dose) | -10.95 |
| Placebo | -9.47 |
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Rating ranges from 1 (normal, not at all ill) to 7 (among the most severely ill subjects); higher score = more affected. Change calculated as mean of (value of CGI-S score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 1, Week 2, Week 3
| Intervention | scores on scale (Least Squares Mean) | ||
|---|---|---|---|
| Week 1 (n=202, 206, 200) | Week 2 (n=178, 188, 186) | Week 3 (n=163, 172, 171) | |
| Placebo | -0.39 | -0.73 | -1.00 |
| Ziprasidone (Higher Dose) | -0.35 | -0.70 | -0.94 |
| Ziprasidone (Lower Dose) | -0.43 | -0.74 | -1.13 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal) with anchors at 2-point intervals; total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as mean of (value of MADRS score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 1, Week 2, Week 3
| Intervention | scores on scale (Least Squares Mean) | ||
|---|---|---|---|
| Week 1 (n=202, 205, 200) | Week 2 (n=178, 188, 186) | Week 3 (n=163, 172, 170) | |
| Placebo | -1.11 | -1.71 | -2.90 |
| Ziprasidone (Higher Dose) | -2.16 | -3.27 | -4.20 |
| Ziprasidone (Lower Dose) | -2.47 | -3.24 | -3.79 |
PANSS is a 30-item scale to measure severity of psychopathology (16 items); positive scale (7 items); negative scale (7 items); summarized as positive score, negative score, and total score. Scores rated 1 (absent symptoms) to 7 (extreme); total score range 30 to 210: higher score indicates greater severity. Change calculated as mean of (value of PANSS score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 3
| Intervention | scores on scale (Least Squares Mean) | ||
|---|---|---|---|
| Week 3 total score (n=198, 199, 189) | Week 3 positive score (n=198, 199, 189) | Week 3 negative score (n=198, 199, 189) | |
| Placebo | -3.44 | -1.56 | -0.20 |
| Ziprasidone (Higher Dose) | -4.87 | -1.94 | -0.58 |
| Ziprasidone (Lower Dose) | -5.34 | -2.26 | -0.43 |
YMRS is an 11-item scale (elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, speech [rate and amount], language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight) used to assess the severity of manic symptoms and effect of treatment on mania severity. Seven items ranked on scale from 0 to 4; 4 items ranked 0 to 8. Total possible score 0 to 60: higher scores indicate greater severity. Change calculated as mean of (value of YMRS score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 1, Week 2
| Intervention | scores on scale (Least Squares Mean) | |
|---|---|---|
| Week 1 (n=202, 205, 200) | Week 2 (n=178, 188, 186) | |
| Placebo | -5.10 | -8.24 |
| Ziprasidone (Higher Dose) | -4.38 | -7.10 |
| Ziprasidone (Lower Dose) | -4.56 | -7.56 |
CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse); higher score = more affected. (NCT00312494)
Timeframe: Week 1, Week 2, Week 3
| Intervention | scores on scale (Least Squares Mean) | ||
|---|---|---|---|
| Week 1 (n=202, 206, 200) | Week 2 (n=178, 188, 186) | Week 3 (n=163, 172, 171) | |
| Placebo | 3.38 | 2.98 | 2.72 |
| Ziprasidone (Higher Dose) | 3.34 | 3.02 | 2.65 |
| Ziprasidone (Lower Dose) | 3.34 | 2.91 | 2.57 |
1 review available for valproic acid and Basal Ganglia Diseases
| Article | Year |
|---|---|
Intravenous Migraine Treatment in Children and Adolescents.
Topics: Administration, Intravenous; Adolescent; Akathisia, Drug-Induced; Anesthetics, Local; Anti-Inflammat | 2020 |
10 trials available for valproic acid and Basal Ganglia Diseases
| Article | Year |
|---|---|
Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; | 2015 |
Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antimanic Agents; Basal Ganglia Diseases; Bipolar Disorder; | 2012 |
Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial.
Topics: Adult; Aged; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Brief | 2003 |
Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseas | 2005 |
Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorde | 2008 |
A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania.
Topics: Acute Disease; Administration, Oral; Adult; Basal Ganglia Diseases; Bipolar Disorder; Haloperidol; H | 1996 |
Combined treatment of schizophrenic psychoses with haloperidol and valproate.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Biperiden; Brief Psychiatric Rating Scale; Chlo | 1998 |
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Body Weight; | 2000 |
Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents | 2002 |
Meige syndrome: double-blind crossover study of sodium valproate.
Topics: Basal Ganglia Diseases; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; Meige Sy | 1987 |
10 other studies available for valproic acid and Basal Ganglia Diseases
| Article | Year |
|---|---|
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2013 |
[Iatrogenic dementia and extrapyramidal syndrome: rare adverse effect of valproic acid-aspirin combination].
Topics: Aged; Anticonvulsants; Aspirin; Basal Ganglia Diseases; Dementia; Drug Interactions; Drug Therapy, C | 2010 |
Valproate-induced hyperammonemic encephalopathy.
Topics: Ammonia; Anticonvulsants; Basal Ganglia Diseases; Brain Diseases, Metabolic; Diagnosis, Differential | 2003 |
Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Topics: Adult; Akathisia, Drug-Induced; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Basal Gangl | 2006 |
Imipramine, methylphenidate and valproic acid-related EPS in a child: a case report.
Topics: Basal Ganglia Diseases; Child; Female; Humans; Imipramine; Methylphenidate; Valproic Acid | 2007 |
Extrapyramidal syndrome due to valproate administration as an adjunct to lithium in an elderly manic patient.
Topics: Aged; Antimanic Agents; Basal Ganglia Diseases; Bipolar Disorder; Drug Therapy, Combination; Female; | 1997 |
Risperidone in the elderly: a pharmacoepidemiologic study.
Topics: Age Factors; Aged; Aged, 80 and over; Basal Ganglia Diseases; Cardiovascular Diseases; Comorbidity; | 1997 |
Extrapyramidal symptoms associated with the adjunct of nortriptyline to a venlafaxine-valproic acid combination.
Topics: Aged; Anticonvulsants; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; B | 1999 |
Extrapyramidal syndrome with sodium valproate.
Topics: Basal Ganglia Diseases; Humans; Male; Middle Aged; Schizophrenia; Valproic Acid | 1979 |
Persistent hemiballismus with lesions outside the subthalamic nucleus.
Topics: Aged; Basal Ganglia Diseases; Corpus Striatum; Humans; Male; Middle Aged; Movement Disorders; Pimozi | 1985 |